RECENT COMMENTS

  • Fatima: Please write your comment here   »Read more
  • Gabriella Tedone: I agree! It is really important to have a correct diagnosis, a wrong diagnosis couuld have [...]   »Read more
  • Vishnu Acharya: You are right. No death can be lightly taken especially by the carer. However the mental p [...]   »Read more
  • Ágnes Riskó: I'm a clinical psychologist working together with physiotherapists in National Institute o [...]   »Read more
  • niki: I'm gynaecologist syrgeon of breast cancer I completely agree but it is difficult to co [...]   »Read more
  • Ashour Hassan Ashour: Like this page   »Read more
  • Joaquim da Cruz Domingos: Dear Sirs, For cancer prostate diagnosed patients there is an old controversy about using [...]   »Read more
  • Jacob Scott: I have started a cancer focused blog at cancerconnector.blogspot.com and can be followed o [...]   »Read more
  • John Fuselier: Why isn/t non cancerous cachexia recognized? It does happen, even without anorexia.   »Read more
  • Henry R Shibata: A thoughtful and timely article. Agree with the sentiments expressed and only wish that [...]   »Read more

Overview of Cancer World

Welcome to Cancer World

The aim of Cancer World is to help reduce the unacceptable number of deaths from cancer that is caused by late diagnosis and inadequate cancer care. We know our success in preventing and treating cancer depends on many factors. Tumour biology, the extent of available knowledge and the nature of care delivered all play a role. But equally important are the political, financial, bureaucratic decisions that affect how far and how fast innovative therapies, techniques and technologies are adopted into mainstream practice. Cancer World explores the complexity of cancer care from all these very different viewpoints, and offers readers insight into the myriad decisions that shape their professional and personal world. 

Cancer World’s strength lies not only in its broad approach, but also in its commitment to exploring issues through the lives and work of those in the field. The magazine gives a voice to health professionals in all fields and at all levels, and offers a platform to those who are most affected by cancer – the people with the disease. 

Cancer World includes in-depth interviews with some of Europe’s most influential oncology leaders, who are invited to comment on breaking news, discuss complex and difficult issues and share their experiences in overcoming personal and professional challenges as they have pushed forward the boundaries of their practice. The magazine also features interviews with people with a high public profile that have an important impact on cancer care – they shape public attitudes and influence how cancer services are delivered and research conducted. We hope that these stories will give our readers a broader perspective on cancer and perhaps inspire some initiatives that will help improve the care that cancer patients receive. 

Cancer World is published six times a year by the European School of Oncology. It is distributed at major conferences, mailed to subscribers and to European opinion leaders, and can be viewed at and downloaded from the Cancer World website.

 ________________________________________________________________________________________________

Copyright©2005 European School of Oncology. All rights reserved 

Registrazione Tribunale di Roma Decreto n.436 del 8.11.2004

 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Boehringer Ingelheim, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Helsinn, Merck Serono, Novartis, Roche and Sanofi Aventis.